Effectiveness of zinc acetate hydrate supplementation in chronic kidney disease patients

Not Applicable

• Conditions: chronic kidney disease

• Registration Number: JPRN-jRCTs061210030
• Lead Sponsor: Itano Seiji

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-08-27
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1) 20 years or older
2) Patient whose most recent clinical tests performed within 12 weeks prior to enrollment meet all of the following criteria
eGFR less than 60 ml/min/1.73 m2
serum zinc level less than 60 micro g/dl
3) Patient who provide written informed consent

Exclusion Criteria

1) Patient with a serum copper concentration of less than 60 micro g/dl on the most recent laboratory tests performed within 12 weeks prior to enrollment
2) Patient who continuously receives hemodialysis and peritoneal dialysis
3) Patient with kidney transplantation
4) Patient with active cancer, and receiving antineoplastic agent
5) Patient with a history of upper gastrointestinal resection
6) Patient with a history of allergy or anaphylaxis of the Zinc-containing preparation
7) Patient who receives the Zinc-containing preparation or the Zinc-containing supplement within 4 weeks prior to enrollment
8) Patient who are pregnant or breastfeeding
9) Patient deemed ineligible for the study by the principal investigator or sub-investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified